Glaxo/Vertex Agenerase Positioning May Be Based On "Dosing Flexibility"
Executive Summary
Glaxo Wellcome and Vertex will attempt to carve out a market for their HIV-1 protease inhibitor Agenerase on the basis of "dosing flexibility." Agenerase (amprenavir) became the fifth protease inhibitor in the U.S. after its accelerated approval by FDA April 15.